RELMADA THERAPEUTICS, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Relmada Therapeutics, Inc. (Nasdaq: RLMD) on June 17, 2025. The report discloses a material corporate event under Item 7.01 (Regulation FD Disclosure) regarding a senior executive appointment.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused on a specific event and does not contain financial statements or performance metrics.
Material Changes
The primary material change disclosed is the appointment of Raj S. Pruthi, MD, as the Company's Chief Medical Officer-Urology. This announcement was made via a press release issued on June 17, 2025.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, forward-looking outlook statements, or specific risk factors beyond the standard legal disclaimers. The information regarding the executive appointment is deemed "furnished" rather than "filed" and is not incorporated by reference into other SEC filings.
Key Facts for Investor Verification
- Verify the background and qualifications of the newly appointed Chief Medical Officer-Urology, Raj S. Pruthi, MD.
- Confirm the effective date of the appointment and any associated compensation arrangements, which may be detailed in the attached press release (Exhibit 99.1).
- Note that this 8-K does not include financial results; investors should refer to the most recent 10-Q or 10-K for financial data.